{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:57:54Z","timestamp":1793858274106,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences & Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-2-009"],"award-info":[{"award-number":["2023-I2M-2-009"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118588","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T15:43:24Z","timestamp":1768664604000},"page":"118588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of benzimidazo-2-amino-1,3,4-thiadiazole carboxylate small-molecule STAT3 inhibitors for colorectal carcinoma therapy"],"prefix":"10.1016","volume":"306","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1030-1336","authenticated-orcid":false,"given":"Ru","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-Bei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9496-2280","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118588_bib1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118588_bib2","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118588_bib3","first-page":"89","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Przegl\u0105d Gastroenterol."},{"key":"10.1016\/j.ejmech.2026.118588_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/codi.15920","article-title":"Do or doughnut: a systematic review and pooled analysis on the utility of pathological evaluation of the anastomotic doughnut in oncological colorectal operations","volume":"24","author":"Wlodarczyk","year":"2022","journal-title":"Colorectal Dis."},{"key":"10.1016\/j.ejmech.2026.118588_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14712598.2019.1595580","article-title":"FOLFOXIRI plus biologics in advanced colorectal cancer","volume":"19","author":"Garc\u00eda-Alfonso","year":"2019","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.118588_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438466","article-title":"State-of-the-art management of colorectal cancer: treatment advances and innovation","volume":"44","author":"Pathak","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ejmech.2026.118588_bib7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118588_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3892\/ol.2021.12998","article-title":"TAGLN2 promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of colorectal cancer cells by activating STAT3 signaling through ANXA2","volume":"22","author":"Zhao","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2026.118588_bib9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s12094-019-02267-9","article-title":"Maintenance treatment in metastatic colorectal cancer: in search of the best strategy","volume":"22","author":"Ron","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejmech.2026.118588_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: asco guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118588_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1186\/s12885-022-09889-3","article-title":"Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2026.118588_bib12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-021-01501-5","article-title":"Encorafenib: a review in metastatic colorectal cancer with a braf v600e mutation","volume":"81","author":"Al-Salama","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118588_bib13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.trecan.2024.05.001","article-title":"Advancements in combining targeted therapy and immunotherapy for colorectal cancer","volume":"10","author":"Singh","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2026.118588_bib14","first-page":"618","article-title":"CAR-T therapy for the treatment of colorectal cancer, Discov","volume":"37","author":"Lecumberri","year":"2025","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.ejmech.2026.118588_bib15","first-page":"199","article-title":"KRAS G12C inhibitors in the treatment of metastatic colorectal cancer, Clin","volume":"23","author":"Xiao","year":"2024","journal-title":"Colorectal Cancer"},{"key":"10.1016\/j.ejmech.2026.118588_bib16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41401-024-01258-z","article-title":"Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2\/STAT3\/GPX4 axis","volume":"45","author":"Lai","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.118588_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jcmm.16134","article-title":"Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway","volume":"25","author":"Yang","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118588_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-023-03202-3","article-title":"Interplay of miRNAs and lncRNAs in STAT3 signaling pathway in colorectal cancer progression","volume":"24","author":"Rahbar Farzam","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2026.118588_bib19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/biomedicines9081016","article-title":"Targeting STAT3 signaling pathway in colorectal cancer","volume":"9","author":"Gargalionis","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118588_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.124","article-title":"STAT3 pathway in cancers: past, present, and future","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118588_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","article-title":"Novel activators and small-molecule inhibitors of STAT3 in cancer","volume":"49","author":"Yang","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2026.118588_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","article-title":"Feedback activation of STAT3 as a cancer drug-resistance mechanism","volume":"37","author":"Zhao","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118588_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41419-024-07297-y","article-title":"Exosomal miR-320d promotes angiogenesis and colorectal cancer metastasis via targeting GNAI1 to affect the JAK2\/STAT3 signaling pathway","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118588_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13046-024-02958-4","article-title":"JAK\/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors","volume":"43","author":"Pennel","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118588_bib25","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10147-021-01987-9","article-title":"Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer","volume":"26","author":"Taniguchi","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118588_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118588_bib27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/mc.70022","article-title":"Inhibition of growth and survival of head and neck cancer cells by silibinin involves the down-regulation of Erk1\/2, AKT and STAT3 signaling","volume":"64","author":"Singh","year":"2025","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2026.118588_bib28","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006178","article-title":"WP1066 induces cell death in a schwannomatosis patient-derived schwannoma cell line, Cold Spring Harb","volume":"8","author":"Allaf","year":"2022","journal-title":"Mol. Case Stud."},{"key":"10.1016\/j.ejmech.2026.118588_bib29","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2022-0005","article-title":"A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma","volume":"11","author":"Groot","year":"2022","journal-title":"CNS Oncol."},{"key":"10.1016\/j.ejmech.2026.118588_bib30","article-title":"First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients","author":"Castellino","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2026.118588_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.70066","article-title":"ACT001 inhibits tumor progression and modulates immune responses in non-small cell lung cancer","volume":"39","author":"Shi","year":"2025","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ejmech.2026.118588_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acscentsci.3c01440","article-title":"Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment","volume":"10","author":"Chen","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.118588_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-025-01674-6","article-title":"Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118588_bib34","article-title":"Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer","volume":"3","author":"Tang","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.ejmech.2026.118588_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118588_bib36","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.ccell.2025.07.015","article-title":"Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: from murine models to a phase 1 clinical trial in pet cats with oral cancer","volume":"43","author":"Grandis","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118588_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2468-1253(18)30009-8","article-title":"Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial","volume":"3","author":"Jonker","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118588_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biopha.2013.03.020","article-title":"Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway","volume":"67","author":"Kamran","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.118588_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107565","article-title":"Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3","volume":"150","author":"Fan","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118588_bib40","doi-asserted-by":"crossref","first-page":"12373","DOI":"10.1021\/acs.jmedchem.3c00863","article-title":"Discovery, optimization, and evaluation of novel N-(benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine analogues as potent STAT3 inhibitors for cancer treatment","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118588_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118020","article-title":"Discovery of potent and selective STAT3 inhibitors against triple-negative breast cancer","volume":"298","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118588_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41571-023-00834-2","article-title":"Personalizing adjuvant therapy for patients with colorectal cancer","volume":"21","author":"Yang","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118588_bib43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/pharmaceutics16060734","article-title":"Review of prodrug and nanodelivery strategies to improve the treatment of colorectal cancer with fluoropyrimidine drugs","volume":"16","author":"Sarkar","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.118588_bib44","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00044-022-02952-5","article-title":"Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations","volume":"31","author":"Wang","year":"2022","journal-title":"Med. Chem. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:40:34Z","timestamp":1773967234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"alternative-id":["S0223523426000334"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118588","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of benzimidazo-2-amino-1,3,4-thiadiazole carboxylate small-molecule STAT3 inhibitors for colorectal carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118588"}}